Medical Device
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
Nine $1bn+ alliances were penned in February, and three exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $8.85bn collaboration with Eli Lilly to advance novel medicines in oncology and immunology.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.
Device-based neurotherapeutics face a coverage gap that drug developers do not, and as the field moves toward combination approaches, that asymmetry could undermine important innovation.
Device-based neurotherapeutics face a coverage gap that drug developers do not, and as the field moves toward combination approaches, that asymmetry could undermine important innovation.